Portage Free Cash Flow Yield vs Cash Ratio Analysis
| PRTG Stock | USD 4.18 0.03 0.71% |
Portage Biotech financial indicator trend analysis is much more than just breaking down Portage Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Portage Biotech is a good investment. Please check the relationship between Portage Biotech Free Cash Flow Yield and its Cash Ratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.
Free Cash Flow Yield vs Cash Ratio
Free Cash Flow Yield vs Cash Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Portage Biotech Free Cash Flow Yield account and Cash Ratio. At this time, the significance of the direction appears to have weak relationship.
The correlation between Portage Biotech's Free Cash Flow Yield and Cash Ratio is 0.31. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Cash Ratio in the same time period over historical financial statements of Portage Biotech, assuming nothing else is changed. The correlation between historical values of Portage Biotech's Free Cash Flow Yield and Cash Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Portage Biotech are associated (or correlated) with its Cash Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Ratio has no effect on the direction of Free Cash Flow Yield i.e., Portage Biotech's Free Cash Flow Yield and Cash Ratio go up and down completely randomly.
Correlation Coefficient | 0.31 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Cash Ratio
Most indicators from Portage Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Portage Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.At this time, Portage Biotech's Issuance Of Capital Stock is most likely to increase significantly in the upcoming years. The Portage Biotech's current Enterprise Value is estimated to increase to about 365.1 M, while Selling General Administrative is projected to decrease to roughly 3.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 15.6M | 16.6M | 18.3M | 19.2M | Depreciation And Amortization | 15.6M | 1K | 54K | 51.3K |
Portage Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Portage Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Portage Biotech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 173.2M | 174.9M | 194.7M | 99.1M | 7.8M | 7.4M | |
| Other Current Liab | 1.9M | 2.9M | 595K | 1.6M | 2.4M | 2.5M | |
| Total Current Liabilities | 2.6M | 3.2M | 783K | 1.9M | 2.9M | 3.0M | |
| Total Stockholder Equity | 96.5M | 101.4M | 121.2M | 76.0M | 4.0M | 3.8M | |
| Net Debt | 509K | (2.6M) | (23.4M) | (10.5M) | (5.0M) | (4.7M) | |
| Retained Earnings | (22.3M) | (38.1M) | (55.0M) | (159.6M) | (239.3M) | (227.4M) | |
| Cash | 3.2M | 2.8M | 23.4M | 10.5M | 5.0M | 3.2M | |
| Non Current Assets Total | 169.4M | 169.9M | 169.8M | 85.5M | 84K | 79.8K | |
| Cash And Short Term Investments | 3.2M | 2.8M | 23.4M | 10.5M | 5.0M | 6.1M | |
| Common Stock Shares Outstanding | 11.0M | 11.7M | 13.1M | 16.1M | 20.3M | 21.4M | |
| Liabilities And Stockholders Equity | 173.2M | 174.9M | 194.7M | 99.1M | 7.8M | 7.4M | |
| Other Stockholder Equity | 58K | 8.0M | 16.9M | 21.2M | 24.4M | 13.3M | |
| Total Liab | 27.5M | 27.3M | 29.2M | 23.7M | 4.5M | 6.1M | |
| Total Current Assets | 3.8M | 4.9M | 24.8M | 13.7M | 7.7M | 7.1M | |
| Common Stock | 117.8M | 130.6M | 158.3M | 218.8M | 219.5M | 230.5M | |
| Short Long Term Debt Total | 3.7M | 3.7M | 150K | 47K | 54.1K | 51.3K | |
| Non Currrent Assets Other | 34K | 58K | 36K | 877K | 49K | 46.6K | |
| Other Assets | 117.4M | 117.4M | 117.4M | 1.0 | 1.15 | 1.09 | |
| Non Current Liabilities Total | 25.0M | 24.1M | 28.4M | 21.9M | 1.6M | 1.5M | |
| Other Current Assets | 14K | 1.5M | 1.3M | 2.4M | 2.6M | 2.8M | |
| Accounts Payable | 343K | 113K | 188K | 274K | 482K | 304.4K | |
| Net Receivables | 60K | 2.2M | 209K | 682K | 39K | 37.1K | |
| Accumulated Other Comprehensive Income | 32K | 82K | 958K | (4.3M) | 23.8M | 25.0M | |
| Net Tangible Assets | 56.4M | 53.2M | 58.1M | 77.9M | 89.6M | 57.7M | |
| Long Term Investments | 6.4M | 8.6M | 9.1M | 9.1M | 2.9M | 0.0 | |
| Net Invested Capital | 100.2M | 101.6M | 121.2M | 76.0M | 4.0M | 3.8M | |
| Net Working Capital | 1.2M | 1.7M | 24.0M | 11.8M | 4.8M | 8.8M | |
| Capital Stock | 117.8M | 130.6M | 158.3M | 218.8M | 219.5M | 176.2M |
Currently Active Assets on Macroaxis
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (68.17) | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.